WPD Pharmaceuticals Inc. (WPDPF) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Vancouver, BC, 加拿大. 现任CEO为 Mariusz Olejniczak.
WPDPF 拥有 IPO日期为 2020-01-13, 16 名全职员工, 在 Other OTC, 市值为 $140.00.
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
